CellSeed Of Japan Establishes French Subsidiary To Market Corneas
This article was originally published in PharmAsia News
The Japanese bioventure CellSeed says it has set up a unit in France to serve the European market for the regenerative corneas it is developing. CellSeed, a spinoff of Tokyo Women's Medical University Hospital, has the corneas undergoing clinical trials in France. The products are to be used in transplants of cultured corneas. (Click here for more - a subscription may be required
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.